MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

L. Lamm, Donald; A. Blumenstein, Brent; D. Crissman, John; E. Montie, James; E. Gottesman, James; A. Lowe, Bruce; F. Sarosdy, Michael; D. BOHL, ROBERT; Barton Grossman, H.; Beck, Thomas; T. Leimert, Joseph; David Crawford, E.

doi:10.1016/s0022-5347(05)67707-5

Public

MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

Shared by NobleBlocks on Apr 1, 2000 • 12:00 AM UTC

Authors:

Donald L. Lamm

Brent A. Blumenstein

John D. Crissman

Abstract

PURPOSE: Bacillus Calmette-Guerin (BCG) immunotherapy has been widely accepted as the optimal treatment for carcinoma in situ and high grade superficial transitional cell carcinoma. However, controversy remains regarding the role of maintenance therapy, and its long-term effect on recurrence and pro...

Subject

Medicine

Transitional cell carcinoma

Immunotherapy

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!